Business
Aquestive develops and manufactures medicines using delivery technologies, including oral film, and is advancing a non-device epinephrine prodrug candidate under the Anaphylm name.
Aquestive revenue fell 22.6% to $44.5M, while the net loss widened to $83.8M and free cash flow fell further negative.
The read at a glance✓ Audited against SEC data
- Business mix — Drug delivery and epinephrine pipelineNote
- Revenue — Revenue fell 22.6% to $44.5MWatch
- Profitability — Net loss widened to $83.8MWatch
- Cash — FCF was negative $53.0MWatch
- Balance sheet — Debt flat; equity less negativeNote
- Insiders — 0 buys / 15 sellsWatch
- Accounting — Altman-Z distress; EQ greyWatch
Where the revenue comes from
Fiscal 2025, as Aquestive Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Manufacture and supply revenue$40.2M
- License and royalty revenue$3.5M
- Co-development and research fees$1.3M
- Royalty$938K
Leadership changes
From Aquestive Therapeutics, Inc.'s own filings, the day they're filed.
- Thomas A. Zalewski · Chief Legal Officer · appointmenteff. 2026-04-02
- Lori J. Braender · Chief Legal Officer · departureeff. 2026-04-02
- Alliance Management · President · appointment
Latest filings
- 8-K · Company announcement2026-08-11
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-08-10
- 8-K · Company announcement2026-06-10
- 10-Q · Quarterly report2026-05-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Aquestive Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.